HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients--evaluation of appropriate research design and methodology to measure symptoms.

Abstract
The development of new chemotherapeutic agents and regimens has contributed to reduced risk of cancer recurrence and prolonged patient survival. However, mild cognitive impairment (MCI), also known as ''chemofog'' or ''chemobrain'' following adjuvant chemotherapy for breast cancer has been reported since the late 1980s. Unfortunately, little is known about it's mechanism, type, severity, and episode length. This article reviewed related studies on the subject, and found that chemotherapy-induced MCI appears to occur in 10-40% of patients, and memory loss and lack of concentration are the most frequent symptoms. The symptoms are apparently transient, but take at least several years to disappear. Reviewed studies show a lack of clear understanding of what causes MCI directly. There is also a lack of consistency in symptom measurement. We point to the need to conduct well-designed studies which begin with a proper hypothesis. Future research needs to be randomized and longitudinal with a base measurement point before the chemotherapy cycle starts. Future studies must adopt an effective and sensitive method to measure MCI. The latest imaging technique, positron emission tomography (PET) may be a powerful tool. Also, all confounding factors, such as age, education, intelligence quotient (IQ), fatigue and depression, hormonal therapy and other treatments should be controlled within the study design. It is hoped that the results of such future studies will allow medical professionals to contemplate effective prevention, treatment and rehabilitation for MCI.
AuthorsTomohiro Matsuda, Tomoko Takayama, Manabu Tashiro, Yu Nakamura, Yasuo Ohashi, Kojiro Shimozuma
JournalBreast cancer (Tokyo, Japan) (Breast Cancer) Vol. 12 Issue 4 Pg. 279-87 ( 2005) ISSN: 1340-6868 [Print] Japan
PMID16286908 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Topics
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Breast Neoplasms (drug therapy)
  • Chemotherapy, Adjuvant (adverse effects)
  • Cognition Disorders (chemically induced)
  • Depression
  • Endpoint Determination
  • Fatigue (etiology)
  • Female
  • Humans
  • Intelligence
  • Longitudinal Studies
  • Positron-Emission Tomography
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Research Design

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: